Bibliography
- WHO/Diabetes. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ [Last accessed 18 March 2014]
- Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
- FDA news release: FDA approves Invokana to treat type 2 diabetes. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm [Accessed 31 March 2014]
- FDA news release: FDA approves Farxiga to treat type 2 diabetes. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm [Accessed 31 March 2014]
- Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicentre, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-50
- Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
- Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
- Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
- Arechevaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, not inferiority trial. Diabetes Obes Metab 2011;13:160-8
- Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012;379:2262-9
- Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2013;76:432-44
- Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85(4):962-71
- Dapagliflozin (Forxiga): Summary of product characteristics. Bristol-Myers Squibb, Uxbridge, UK; 2014. Available from: http://www.medicines.org.uk/EMC/medicine/27188 [Accessed 31 March 2014]
- ClinicalTrials.gov Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). Available from: http://clinicaltrials.gov/ct2/show/NCT01944618?term=dapagliflozin&rank=33 [Accessed 31 March 2014]
- Doggrell SA. Clinical trials with thiazolidinediones in subjects with type 2 diabetes – is pioglitazone any different from rosiglitazone. Expert Opin Pharmacother 2008;9:405-20
- Vasilakou S, Karagiannis T, Athanasiadou E, et al. Sodium-glucose contransporter 2 inhibitors for type 2 diabetes; a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74